Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 target price on the biotechnology company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday, January 13th.

Anavex Life Sciences Stock Performance

NASDAQ:AVXL opened at $10.20 on Tuesday. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44. The stock has a fifty day moving average of $9.81 and a 200 day moving average of $7.35. The firm has a market capitalization of $865.16 million, a price-to-earnings ratio of -19.62 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities analysts forecast that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

Large investors have recently made changes to their positions in the business. Orion Capital Management LLC lifted its holdings in Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after buying an additional 10,000 shares during the period. PVG Asset Management Corp purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter worth approximately $74,000. Atria Investments Inc bought a new position in shares of Anavex Life Sciences during the third quarter valued at $76,000. BNP Paribas Financial Markets increased its stake in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 7,421 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Anavex Life Sciences by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 6,366 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.